Literature DB >> 7287056

Alternate complement pathway activation by recluse spider venom.

G Kurpiewski, B J Campbell, L J Forrester, J T Barrett.   

Abstract

Venom from the poisonous brown recluse spider (Loxosceles reclusa) catalyses the lysis of dithiothreitol-treated human erythrocytes when incubated with serum complement but not in heat inactivated serum, a characteristic of complement system activation via the alternate pathway. This activity of the venom was shown to reside in a Sephadex G-75 fraction of the venom which also contains the dermonecrotoxin. Isoelectric focusing of this fraction identified the complement inactivating molecules(s) in the region near pH=6. Analysis of complement after interaction with venom indicated a loss of haemolytic C3. Immunoelectrophoretic development of venom-complement mixtures with anti C3 proactivator revealed the appearance of the C3 activator. These data indicate that recluse spider venom activates the alternate complement pathway.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7287056

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  3 in total

1.  Variable Substrate Preference among Phospholipase D Toxins from Sicariid Spiders.

Authors:  Daniel M Lajoie; Sue A Roberts; Pamela A Zobel-Thropp; Jared L Delahaye; Vahe Bandarian; Greta J Binford; Matthew H J Cordes
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

2.  Recombinant Protein Containing B-Cell Epitopes of Different Loxosceles Spider Toxins Generates Neutralizing Antibodies in Immunized Rabbits.

Authors:  Sabrina de Almeida Lima; Clara Guerra-Duarte; Fernanda Costal-Oliveira; Thais Melo Mendes; Luís F M Figueiredo; Daysiane Oliveira; Ricardo A Machado de Avila; Valéria Pereira Ferrer; Dilza Trevisan-Silva; Silvio S Veiga; João C Minozzo; Evanguedes Kalapothakis; Carlos Chávez-Olórtegui
Journal:  Front Immunol       Date:  2018-04-03       Impact factor: 7.561

3.  Brown Recluse spider bite mediated hemolysis: clinical features, a possible role for complement inhibitor therapy, and reduced RBC surface glycophorin A as a potential biomarker of venom exposure.

Authors:  Eric A Gehrie; Hui Nian; Pampee P Young
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.